Yttrium Y-90

Vivos Inc. initiates first human clinical trial for RadioGel® Precision Radionuclide Therapy™ in India, successfully treating five cancer patients. The trial aligns with the protocol designed for the Mayo Clinic, focusing on safety. Vivos continues discussions with the FDA to initiate trials in the U.S., aiming to expand to 30 patients and publish comprehensive data in 2025.

Vivos Inc. initiates first human clinical trial for RadioGel® Precision Radionuclide Therapy™ in India, successfully treating five cancer patients. The trial aligns with the protocol designed for the Mayo Clinic, focusing on safety. Vivos continues discussions with the FDA for U.S. trials, aiming to expand to 30 patients and publish comprehensive data in 2025.

The Global Medical Isotope Market was valued at USD 5.66 billion in 2023 and is projected to reach USD 12.15 billion by 2032, growing at a CAGR of 8.87% driven by increased applications in diagnostics and therapy, particularly in cancer treatment. Key isotopes include technetium-99m, iodine-131, and lutetium-177. The market is influenced by advancements in nuclear medicine, imaging technologies, and personalized treatments, with challenges in supply chain and transportation due to radioactive nature. Major players include GE Healthcare, Jubilant Radiopharma, and Mallinckrodt Pharmaceuticals. North America dominates the market, while Asia-Pacific shows the fastest growth.